Bladder Cancer - Results from #600

REVIEW UroToday

Near-infrared photoimmunotherapy targeting Nectin-4 in a preclinical model of bladder cancer. January 31, 2024

Latin American Consensus for the Evaluation and Treatment of Patients With Metastatic/Locally Advanced Urothelial Carcinoma. January 31, 2024

Characterization of Sarcomatoid Urothelial Bladder Cancer Features and Treatment Options Using Patient-Derived Organoids - Expert Commentary January 30, 2024

Evaluation of a New Cystoscopic Cryocatheter and Method for the In Situ Destruction of Bladder Cancer: Preliminary In vivo Study. January 30, 2024

Loss of TROP2 and epithelial cell adhesion molecule expression is linked to grade progression in pTa but unrelated to disease outcome in pT2-4 urothelial bladder carcinomas. January 30, 2024

A Comprehensive Analysis of Immune Response in Patients with Non-Muscle-Invasive Bladder Cancer. January 29, 2024

OncoTherad® is an immunomodulator of biological response that downregulate RANK/RANKL signaling pathway and PD-1/PD-L1 immune checkpoint in non-muscle invasive bladder cancer. January 29, 2024

A comparative analysis of radical cystectomy with perioperative chemotherapy, chemoradiation therapy, or systemic therapy in patients with clinically advanced node-positive bladder cancer (cN2/N3). January 29, 2024

The Elusive Horizon: Biomarkers in Urothelial Carcinoma. January 29, 2024

Immunomodulatory effects and improved outcomes with cisplatin- versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer. January 29, 2024

Targeting STAT3 in tumor-associated antigen-presenting cells as a strategy for kidney and bladder cancer immunotherapy. January 26, 2024

Bladder sparing by short-course radiotherapy combined with toripalimab in high-risk/extremely high-risk non-muscle invasive bladder cancer (HOPE-04): study protocol for a single-arm, prospective, phase II trial. January 26, 2024

Neoadjuvant immunotherapy and chemoimmunotherapy for stage II-III muscle invasive bladder cancer. January 26, 2024

CG Oncology Announces Pricing of Upsized Initial Public Offering January 25, 2024

The association between frailty, hypogonadism, and postoperative outcomes among men undergoing radical cystectomy. January 25, 2024

Combination intravesical chemotherapy for non-muscle invasive bladder cancer (NMIBC) as first-line or rescue therapy: where do we stand Now? January 25, 2024

HER2 Expression in Bladder Cancer: A Focused View on Its Diagnostic, Prognostic, and Predictive Role. January 25, 2024

Human Epidermal Growth Factor Receptor 2 Overexpression in Micropapillary and Other Variants of Urothelial Carcinoma. January 25, 2024

Clinical Outcomes after Robot-Assisted Radical Cystectomy versus Open Radical - Expert Commentary January 24, 2024

Role of Additional MRI-Based Morphologic Measurements on the Performance of VI-RADS for Muscle-Invasive Bladder Cancer. January 24, 2024

Page 31 of 517